The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Biocept, Inc. (BIOC) one of those stocks right now? A quick ...

A week ago, Biocept, Inc. (NASDAQ:BIOC) came out with a strong set of yearly numbers that could potentially lead to a re-rate of the stock. The results were impressive, with revenues of US$27m ...

Biocept Inc (NASDAQ:BIOC): Hal Mintz’s Sabby Capital filed an amended 13D. You can check out Sabby Capital’s latest holdings and filings here. Please follow Sabby Capital (if you aren’t already doing ...

A Chapter 7 bankruptcy discharge absolves the company from the legal obligation to repay most unsecured debts. Last month, Biocept signed a deal with Plus Therapeutics Inc. Get the data-driven signals ...

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (NasdaqCM: BIOC) today announced that it has commenced a process to explore and evaluate strategic alternatives to enhance shareholder value. Biocept has ...

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and service, announces that management will present ...

Maxim Group analyst Jason McCarthy maintained a Hold rating on Biocept (BIOC – Research Report) yesterday. The company’s shares opened today at $0.94. McCarthy covers the Healthcare sector, focusing ...

SAN DIEGO, March 7, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to ...

SAN DIEGO, Dec. 14, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with ...

SAN DIEGO, Sept. 10, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to ...